{"id":3294,"date":"2009-07-09T15:13:09","date_gmt":"2009-07-09T19:13:09","guid":{"rendered":"https:\/\/www.orthodoxytoday.org\/blog\/?p=3294"},"modified":"2009-07-09T15:13:09","modified_gmt":"2009-07-09T19:13:09","slug":"ge-to-test-drug-toxicity-on-human-embryos-not-lab-rats","status":"publish","type":"post","link":"https:\/\/www.orthodoxytoday.org\/blog\/2009\/07\/ge-to-test-drug-toxicity-on-human-embryos-not-lab-rats\/","title":{"rendered":"GE to Test Drug Toxicity on Human Embryos, Not Lab Rats"},"content":{"rendered":"

Here we go down the slippery slope. PETA will be very happy that rats will be spared.<\/em>
\nCNSNews<\/a> | Monica Gabriel | July 9, 2009<\/p>\n

GE Healthcare, the medical research subsidiary of General Electric, has formed a partnership with a leading U.S. biotech company to develop products based on human embryonic stem cells that can be used to develop new drugs. <\/p>\n

On June 30, GE Healthcare and Geron Corporation announced a multi-year alliance where Geron will provide GE scientists with an undisclosed amount of human embryonic stem cells. <\/p>\n

The human cells will be used \u201cto develop and commercialize cellular assay products derived from human embryonic stem cells (hESCs) for use in drug discovery, development and toxicity screening,\u201d according to a news release. <\/p>\n

GE Healthcare, which is based in Britain, hopes that human embryonic testing will spare lab rats from having potentially toxic drugs in or on the animals. <\/p>\n

“This could replace, to a large extent, animal trials,” Konstantin Fiedler, general manager of cell technologies at GE Healthcare, told Reuters.<\/p>\n

“Once you have human cells and you can get them in a standardized way, like you get right now, your lab rats in a standardized way, you can actually do those experiments on those cells,” he added.<\/p>\n

Cells derived from Human Embryonic Stem Cells \u201chave similar attributes to their counterparts in the body, and can therefore be used to predict many pharmacological characteristics of a drug candidate,\u201d according to the Geron\/GE news release.<\/p>\n

Geron said the cells to be used under the pact with GE were derived from embryonic stem cells that were listed on the National Institutes of Health Human Pluripotent Stem Cell Registry. The reigstry contains stem-cell lines approved under policies established by the Bush administration in 2001.<\/p>\n

“We acknowledge the considerable debate and take very seriously the ethical and societal issues associated with research using stem cells derived from embryonic or fetal tissue,\u201d the companies said. \u201cWe conduct our research in an ethically and scientifically responsible manner.”<\/p>\n

Dr. David Prentice, senior fellow for life science at the Family Research Council, told CNSNews.com, that embryos must be killed before stem cells can be derived from them for research purposes. <\/p>\n

\u201cHuman embryonic stem cell research is ethically irresponsible and scientifically unworthy, as well as useless for patients,\u201d Prentice said. <\/p>\n

Prentice explained that General Electric\u2019s optimism in saving lab animals from testing by using hESCs is also largely unfounded.<\/p>\n

\u201cThere is always going to be a problem on trying to rely just on cultured cells to do drug testing,\u201d Prentice explained. <\/p>\n

. . . more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Here we go down the slippery slope. PETA will be very happy that rats will be spared. CNSNews | Monica Gabriel | July 9, 2009 GE Healthcare, the medical research subsidiary of General Electric, has formed a partnership with a leading U.S. biotech company to develop products based on human embryonic stem cells that can … Read more<\/a><\/p>\n","protected":false},"author":497,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"generate_page_header":"","footnotes":""},"categories":[15],"tags":[],"class_list":["post-3294","post","type-post","status-publish","format-standard","hentry","category-moral-issues"],"_links":{"self":[{"href":"https:\/\/www.orthodoxytoday.org\/blog\/wp-json\/wp\/v2\/posts\/3294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.orthodoxytoday.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.orthodoxytoday.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.orthodoxytoday.org\/blog\/wp-json\/wp\/v2\/users\/497"}],"replies":[{"embeddable":true,"href":"https:\/\/www.orthodoxytoday.org\/blog\/wp-json\/wp\/v2\/comments?post=3294"}],"version-history":[{"count":0,"href":"https:\/\/www.orthodoxytoday.org\/blog\/wp-json\/wp\/v2\/posts\/3294\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.orthodoxytoday.org\/blog\/wp-json\/wp\/v2\/media?parent=3294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.orthodoxytoday.org\/blog\/wp-json\/wp\/v2\/categories?post=3294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.orthodoxytoday.org\/blog\/wp-json\/wp\/v2\/tags?post=3294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}